Global Genes and RARE-X announced their respective boards of directors have signed a definitive agreement to combine the two organizations. This merger will enable the combined organization to provide next-generation rare disease advocates with the tools and resources they need to accelerate their drive for treatments. The merger is expected to close by December 31, 2022. At that time, Charlene Son Rigby will become CEO of the combined organization.
RARECast Podcast Host Daniel Levine spoke to RARE-X CEO Charlene Son Rigby about what the merger means to patients, advocacy groups, and the whole rare disease ecosystem.